Global Emphysema Treatment Market Size study & Forecast, by Medication Type (Bronchodilators, Steroids, Others) By Distribution Channel (Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies) and Regional Analysis, 2022-2029

Global Emphysema Treatment Market Size study & Forecast, by Medication Type (Bronchodilators, Steroids, Others) By Distribution Channel (Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies) and Regional Analysis, 2022-2029

Global Emphysema Treatment Market is valued approximately USD 4,474.71 million in 2021 and is anticipated to grow with a healthy growth rate of more than 5% over the forecast period 2022-2029. Emphysema Treatment is respiratory diseases. In these conditions, lungs tiny air sac called alveoli stretch out of shape and ruptured as a result these rupture alveoli become damaged and lose its elasticity. As a result, its make difficulty in breathing. The Emphysema Treatment market is expanding because of factors such as increasing Incidence of Cigarette Smoking and increasing prevalence of chronic obstructive pulmonary disease.

According to the Statista consumption of tobacco products rose over the past century, Furthermore, China was the biggest tobacco producer worldwide with an amount of some 2.13 million metric tons of tobacco produced. In addition, annual number of deaths from smoking reached 7.69 million worldwide in 2019. Another important component driving space is the increasing prevalence of chronic obstructive pulmonary disease. As per Statista, COPD is the third leading cause of death globally. In addition, in 2019, around 8.89 million people worldwide died from ischemic heart disease. The biggest modifiable risk factors for heart disease include smoking, unhealthy diet, being overweight, and a lack of exercise. However, side effects of the drug used in Emphysema Treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Emphysema Treatment Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the space in terms of revenue, owing to the high incidences of emphysema and rise in spending in healthcare infrastructure. According to Statista, revenue of North America in the Health Care segment is projected to reach US$20.77bn in 2023 and projected an annual growth rate of 12.25% in between 2023 to 2027.Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising investments in manufacturing of high-quality emphysema drugs in the market space.

Major market player included in this report are:

Pfizer, Inc
Teva pharmaceuticals
Orion corporation
GlaxoSmithKline plc
Hikma Pharmaceuticals plc
Verona Pharma
Novartis AG
AstraZeneca
Boehringer Ingelheim International GmbH
Mylan Pharmaceuticals

Recent Developments in the Market:
 In June 2021 Tevas Launch PERFOROMIST®, Formoterol Fumarate Inhalation Solution, 20 mcg/2 ML, used in treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema., within the United States.

 In July 2022 Mylan Pharmaceutical has got the go-ahead from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct Phase III Clinical Trial of Revefenacin inhalation solution 175 mcg/3ml to treat chronic obstructive pulmonary disease (COPD).

Global Emphysema Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Medication Type, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Medication Type:
Bronchodilators
Steroids
Others

By Distribution Channel:
Online Providers
Drug Stores and Retail Pharmacies
Hospital Pharmacies

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Companies Mentioned

Pfizer, Inc
Teva pharmaceuticals
Orion corporation
GlaxoSmithKline plc
Hikma Pharmaceuticals plc
Verona Pharma
Novartis AG
AstraZeneca
Boehringer Ingelheim International GmbH
Mylan Pharmaceuticals

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.